Curated CRC research, accessible, accurate, actionable

The CRC Digest

Monday, October 12, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  Study evaluates association between stool DNA test kit return and colorectal cancer incidence

  A retrospective cohort study linking claims and laboratory data evaluated the association between multitarget stool DNA (mt-sDNA) test kit return and subsequent colorectal cancer incidence among average-risk adults aged 45-85 who received kits between 2017 and 2019. (Adv Ther)

• ◇ RESEARCH

  P-selectin glycoprotein ligand-1 may link early- and late-onset colorectal cancer pathways

  A review proposes that PSGL-1, a molecule involved in chronic gut inflammation, may function as a molecular bridge between early-onset and late-onset colorectal cancer, offering insight into shared pathophysiological mechanisms. (Biomed Pharmacother)

• ♥ LIVING WITH CRC

  Oxaliplatin detected in vaginal secretions during FOLFOX chemotherapy

  A case report of a 54-year-old woman with stage IIIA rectal cancer found detectable oxaliplatin in vaginal swabs and urine during chemotherapy; urine oxaliplatin levels peaked on the first day after chemotherapy and remained detectable for up to 3 days. (J Med Case Rep)

This week's research spans screening completion, early-onset pathways, and survivorship considerations in colorectal cancer.